ストックスクリーナーアプリを入手
5.78
3.67%
-0.22
前日終値:
$6.00
開ける：
$6.13
24時間の取引高:
2.17M
Relative Volume:
1.13
時価総額：
$441.12M
収益：
$14.79M
当期純損益:
$-102.44M
株価収益率:
-1.9013
EPS:
-3.04
ネットキャッシュフロー:
$-91.73M
1週間 パフォーマンス:
+43.42%
1か月 パフォーマンス:
+77.30%
6か月 パフォーマンス:
-41.91%
1年 パフォーマンス:
-42.43%
1日の値動き範囲:
$5.50
$6.149
1週間の範囲:
$5.04
$7.20
52週間の値動き範囲:
$2.88
$15.05
Solid Biosciences Inc Stock (SLDB) Company Profile
名前
Solid Biosciences Inc
セクター
電話
617-337-4680
住所
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.78 | 441.12M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-13 | 開始されました | Wedbush | Outperform |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-15 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-06-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 再開されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | William Blair | Outperform |
| 2024-03-15 | 開始されました | Citigroup | Buy |
| 2024-03-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-07-12 | 開始されました | Piper Sandler | Neutral |
| 2021-05-27 | 開始されました | Jefferies | Buy |
| 2021-03-16 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2021-01-08 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 開始されました | Evercore ISI | Outperform |
| 2019-08-29 | ダウングレード | Citigroup | Neutral → Sell |
| 2019-08-19 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | ダウングレード | Goldman | Neutral → Sell |
| 2019-02-08 | アップグレード | Citigroup | Sell → Neutral |
| 2019-02-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 開始されました | Citigroup | Sell |
| 2018-09-06 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Solid Biosciences Inc (SLDB) 最新ニュース
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? - MSN
Bain Capital life sciences invests $4.03 million in Solid Biosciences By Investing.com - Investing.com
Solid Biosciences sees $20.15m stock purchase by Perceptive Advisors - Investing.com
Research Analysts Issue Forecasts for SLDB FY2025 Earnings - MarketBeat
Wedbush Increases Earnings Estimates for Solid Biosciences - MarketBeat
Chardan Capital Forecasts Strong Price Appreciation for Solid Biosciences (NASDAQ:SLDB) Stock - Defense World
Solid Biosciences’ stock soars on early success in DMD gene therapy trial - MSN
Solid Biosciences (NASDAQ:SLDB) Given New $16.00 Price Target at Chardan Capital - MarketBeat
Solid Biosciences’ $200 Million Common Stock Offering - Global Legal Chronicle
Wall Street’s Top Picks: Solid Biosciences, Wingstop, and Diamondback Energy - PUNE.NEWS
Wedbush Adjusts Price Target on Solid Biosciences to $18 From $16, Keeps Outperform Rating - Marketscreener.com
Solid Biosciences surges on Duchenne therapy success - The Pharma Letter
Solid Biosciences shares gain on JMP Market Outperform rating By Investing.com - Investing.com South Africa
Solid Biosciences shares gain on JMP Market Outperform rating - Investing.com India
Solid Biosciences CFO Kevin Tan sells $12,529 in stock By Investing.com - Investing.com Nigeria
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move? - MSN
Solid Biosciences' SWOT analysis: gene therapy stock poised for pivotal year - Investing.com Nigeria
Solid Biosciences Inc. (NASDAQ:SLDB) Receives $15.30 Average PT from Analysts - MarketBeat
Solid Biosciences Announces Pricing of Underwritten Offering - GlobeNewswire
Solid Biosciences COO David Howton sells shares worth $22,021 By Investing.com - Investing.com Australia
Solid Biosciences CTO Herzich sells $10,644 in stock By Investing.com - Investing.com South Africa
Solid Biosciences chief regulatory officer sells shares for $12,192 By Investing.com - Investing.com South Africa
Solid Biosciences price target raised to $16 from $15 at Chardan - TipRanks
Solid Biosciences chief medical officer sells $12,893 in stock By Investing.com - Investing.com Canada
Solid Biosciences CEO Alexander Cumbo sells $45,005 in stock By Investing.com - Investing.com Australia
Solid Biosciences’ Gene Therapy SGT-003 Produces Microdystrophin Expression in Patients With DMD - CGTLive™
Solid Biosciences CFO Kevin Tan sells $12,529 in stock - Investing.com
Solid Biosciences CEO Alexander Cumbo sells $45,005 in stock - Investing.com
Solid Biosciences CTO Herzich sells $10,644 in stock - Investing.com
Solid Biosciences COO David Howton sells shares worth $22,021 - Investing.com India
Solid Biosciences Shares Up After Positive Results From Duchenne Drug Study, Prices $200 Million Offering - Marketscreener.com
Solid Biosciences stock soars on promising Duchenne therapy data - Investing.com India
Early DMD gene therapy data powers Solid Bio stock surge - FirstWord Pharma
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data - Benzinga
As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy - Endpoints News
Solid says early data suggest ‘differentiated’ Duchenne gene therapy - BioPharma Dive
Solid Biosciences sets $200 million stock and warrant offering By Investing.com - Investing.com Nigeria
Solid Biosciences jumps on early-stage data from gene therapy - TradingView
Biotech Boom: Solid Biosciences (SLDB) Stock Skyrockets On Positive Developments - Stocks Telegraph
Morning Brew: Marjorie Taylor Greene's Stock Moves and Solid Biosciences' Surge - GuruFocus.com
Duchenne gene therapy from Solid Biosciences produces promising results in early study - STAT
Solid Bio stock rises on data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid soars as early DMD gene therapy data beat expectations - Fierce Biotech
Solid Biosciences sets $200 million stock and warrant offering - Investing.com India
Solid Biosciences Reports Positive Initial Clinical Data from SGT-003 -February 18, 2025 at 06:59 am EST - Marketscreener.com
Massive $200M Capital Raise: Elite Healthcare Investors Back Solid Biosciences Growth Plan - StockTitan
Solid Biosciences reports initial clinical data from INSPIRE DUCHENNE trial - TipRanks
Solid Biosciences Reports Promising Initial Data from Phase 1/2 INSPIRE DUCHENNE Trial for SGT-003 in Duchenne Muscular Dystrophy - Nasdaq
Solid Biosciences Reports Positive Initial Clinical Data - GlobeNewswire
Clinical Trial Breakthrough: Revolutionary Gene Therapy Achieves 110% Dystrophin in Duchenne Patients - StockTitan
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Solid Biosciences Inc (SLDB) 財務データ
収益
当期純利益
現金流量
EPS
Solid Biosciences Inc (SLDB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
| Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):